Vaccines Articles
A study examined whether the vaccine schedule was associated with an increased risk of infections not targeted by vaccines and found no statistically significant differences in estimated cumulative vaccine antigen exposure through the first 23 months of life.
The World Health Organization is recommending a single dose of the typhoid conjugate vaccine for use in infants and children older than 6 months and a catch-up vaccine in children up to 15 years in countries where the infection is endemic.
An Internet panel survey of healthcare personnel (HCP) showed the overall influenza vaccination coverage estimate among HCP was 78.6 percent in the 2016-17 season, an increase of 15 percentage points since the 2010-11 season, but similar to the 2013-14 through 2015-16 seasons, with the highest coverage among those whose workplace had vaccination requirements.
Grifols’ HyperRAB (rabies immune globulin [human]) has been approved by the U.S. Food and Drug Administration to treat rabies postexposure prophylaxis.
Researchers at the University of Oxford have begun a two-year clinical trial to test a universal influenza (flu) vaccine in more than 2,000 patients.
With many reports about this year’s influenza (flu) vaccine ineffectiveness, a new study shows it is more effective than thought, especially among children.
Scientists at the National Institutes of Health, Frederick National Laboratory for Cancer Research and the University of Melbourne in Australia tested a new universal flu vaccine that produced good immunity against several different strains of influenza viruses.
Researchers at the University of Nottingham in England have found evidence that being in a positive mood when receiving an influenza (flu) vaccine can increase its protective effect.
In an effort to understand how current influenza vaccines are influenced by preexisting immunity in people of different ages, researchers vaccinated volunteers ages 18 years to 85 years with split, inactivated Fluzone influenza vaccine in four consecutive seasons from 2013 to 2016, and assessed the impact of repeated vaccination on breadth and durability of antibodies as a result of vaccine strain changes.
GlaxoSmithKline (GSK) has receivedU.S. Food and Drug Administration approval for its Shingrix vaccine to prevent shingles (herpes zoster) in patients 50 years and older.
